At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Visit our website: www.pfizer.com.au
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 40 countries worldwide, with headquarters in Foster City, California.
Visit our website: www.gilead.com
Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.
Visit our website: www.Cepheid.com
A global leader in in-vitro diagnostics for over 55 years, bioMérieux is driven by a pioneering spirit and unrelenting commitment to provide innovative diagnostic solutions that improve patient health. The patient is at the center of our strategy of developing products with high medical and economic value.. Our extensive Antimicrobial Stewardship (AMS) diagnostics range supports appropriate antibiotic use, helping to preserve their efficacy and curb antibiotic resistance. Putting diagnostics at the heart of Antimicrobial Stewardship helps drive informed therapy decisions, providing actionable results to the clinician at every stage of the patient’s healthcare pathway: from initiation of antibiotic therapy, to treatment adjustment and optimization and finally for antibiotic discontinuation. We are present in more than 160 countries worldwide..
Visit our website: www.biomerieux.com
The 32nd International Congress of Antimicrobial Chemotherapy (ICC) Organising Committee invite you to sponsor or exhibit at the Congress. The Congress presents a world class platform for clinicians, scientists, researchers, and other healthcare professionals working in infectious diseases from around the world. There is a wide range of innovative sponsorship opportunities, which will allow companies to engage with the diverse delegate base and take advantage of this outstanding program.
The Congress will provide many long lasting benefits including:
To view the sponsorship and exhibition opportunities available, download the Sponsorship & Exhibition Prospectus here.
Should you have any queries or require more information, please contact the ICC Congress Organisers on 32icc@icms.com.au.
(+61) 3 9810 0200
32icc@icms.com.au
icms.com.au